These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Regression of hepatocellular carcinoma under Tamoxifen: report of one case and review of the literature].
    Author: Macaigne G, Auriault ML, Boivin JF, Cheaib S, Chayette C, Deplus R.
    Journal: Gastroenterol Clin Biol; 2002 Dec; 26(12):1165-7. PubMed ID: 12520204.
    Abstract:
    Hepatocellular carcinoma is a malignant tumor with a poor prognosis, particularly when it is unresectable. The results of tamoxifen treatment in hepatocellular carcinoma have been disappointing and randomized studies have shown conflicting results. We report the case of a 72-yr-old-man with histologically confirmed hepatocellular carcinoma on a normal liver, that regressed with tamoxifen treatment. Regression was confirmed by normalization of serum alpha-fetoprotein levels and a significant decrease in radiological lesions by 66%. The patient was alive in excellent clinical condition more than 30 months after the initial diagnosis.
    [Abstract] [Full Text] [Related] [New Search]